GSK plc

Research GSK plc (GS71) on Bullrun: market cap EUR 86.64B, P/E 15.8, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 86.64B; P/E is 15.8; dividend yield is 2.8%.

Peer valuation comparison

Latest P/E is 15.79x versus a Healthcare sector median of 24.46x (35.5% below).

Latest dividend yield is 2.75% versus a Healthcare sector median of 2.11% (30.3% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025GBP 32.67BGBP 6.29BGBP 6.39B72.4%1.39GBP 3.40BGBP 17.72BGBP 16.38B
FY2024GBP 31.38BGBP 2.95BGBP 5.16B71.2%0.62GBP 3.87BGBP 16.99BGBP 13.67B
FY2023GBP 30.33BGBP 5.31BGBP 5.45B71.8%1.2GBP 2.94BGBP 18.02BGBP 12.80B
FY2022GBP 29.32BGBP 15.62BGBP 6.26B67.4%3.66GBP 3.72BGBP 20.99BGBP 10.10B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28EUR 86.64B15.83.7%0.8

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.8 EUR, yield 2.8%.

YearDividends/share
FY20250.74 GBP
FY20240.71 GBP
FY20230.65 GBP
FY20220.88 GBP

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is GSK plc's market cap?

GSK plc's market capitalization is EUR 86.64B.

What is GSK plc's P/E ratio?

GSK plc's price-to-earnings (P/E) ratio is 15.8.

Does GSK plc pay a dividend?

GSK plc has a dividend yield of 2.8%.

What does GSK plc do?

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.